parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in bergmann glia	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	32 Parkinson's papers of 295	0.54
pathways Reactome	10 pathways; mostly protein handling	0.90

No case: the score is under the bar. Receipt 10247

RING1 in astrocytes, braak+0.42 (p 0.255) → +0.22 (p 0.565)receipt 10255
RING1 in dopamine neurons, braak-0.04 (p 0.910) → -0.04 (p 0.919)receipt 10256

receipt 10256: RING1 in dopamine neurons, braak

power: full sample -0.02 (p 0.942, n 18), 95% CI -0.48 to +0.45. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.02 (p 0.935, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.00 (p 0.997, n 18). could be the mix.
skeptic: leave-one-out range -0.12 to +0.13, sign flips 6; without severely affected donors -0.02 (p 0.942, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for RING1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 10255: RING1 in astrocytes, braak

power: full sample +0.28 (p 0.269, n 18), 95% CI -0.22 to +0.66. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.24 (p 0.337, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.24 (p 0.337, n 18). could be the mix.
skeptic: leave-one-out range +0.19 to +0.43, sign flips 0; without severely affected donors +0.28 (p 0.269, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for RING1 in astrocytes.

case closed: nothing better to follow up.

loading the receipts